Epoetin Alfa and Hemoglobin: Not Indicated for Transfusion Refusal
Epoetin alfa (recombinant human erythropoietin) is approved for anemia associated with chronic kidney disease, chemotherapy, and certain other conditions. However, it is not indicated to raise hemoglobin in patients who decline blood transfusion as a primary strategy. Clinical guidelines reserve erythropoiesis‑stimulating agents for specific indications and hemoglobin thresholds, and they do not support use solely to avoid transfusion in non‑approved settings. Decisions about anemia management in transfusion‑refusing patients should involve a multidisciplinary team (hematology, ethics, critical care) to explore alternatives such as iron optimization, hemostatic agents, and blood conservation techniques.
Blood Disorders - Related Articles
- High Red Blood Cell Count (RBC) vs. White Blood Cell Count (WBC): Causes & Implications
- White Blood Cells: The Body's Defense Force
- Hemophilia: Understanding the Causes, Symptoms & Inheritance
- Boost Hemoglobin Naturally: Dietary & Lifestyle Strategies
- Blood Components: Red Cells, White Cells, Platelets, and Plasma Explained
- High Red Blood Cell Count (Erythrocytosis): Causes and Evaluation
- Infusion Therapy: Understanding Treatment Options, Benefits, and Risks
